|
시장보고서
상품코드
2126671
무릎 골관절염 시장 : 약제 종류별, 투여 경로별, 유통 채널별, 지역별Knee Osteoarthritis Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
무릎 골관절염 시장은 2026년에 92억 2,840만 달러 규모가 될 것으로 추정되며, 2033년까지 198억 4,230만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 11.6%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 92억 2,840만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 11.60% | 2033년 시장 규모 예측: | 198억 4,230만 달러 |
퇴행성 슬관절염(OA)은 무릎 연골을 서서히 파괴하여 통증, 뻣뻣함, 부기, 운동 제한을 유발하는 진행성 관절 질환입니다. 퇴행성 슬관절염은 전 세계에서 가장 흔한 근골격계 질환 중 하나이며, 고령화, 비만, 스포츠 부상, 운동 부족 등의 생활 습관으로 인해 유병률이 증가하는 추세입니다.
퇴행성 슬관절염 시장은 관절통 및 염증 치료제, 관절 내 주사 및 점탄성 보충제, 보조기, 물리치료, 그리고 인공 슬관절 치환술을 포함한 광범위한 외과적 치료 등 여러 부문으로 구성되어 있습니다. 의료비 지출 증가와 정형외과 의료의 지속적인 발전에 힘입어, 혈소판 농축 혈장(PRP), 줄기세포 치료, 퇴행성 관절염 병태 수정제(DMOADs) 등 재생 의학에 대한 관심이 높아지고 있습니다.
시장 역학
세계 무릎 골관절염 시장은 고령화 진행, 비만 유병률 증가, 관절 손상 발생률 상승에 의해 견인되고 있으며, 이러한 요인들은 장기 치료가 필요한 환자층의 확대로 이어지고 있습니다. 조기 진단에 대한 인식 제고, 최첨단 영상 진단 기술에 대한 접근성 향상, 그리고 질환 수정형 퇴행성 관절염 치료제(DMOAD), 생물학적 제제 및 최소침습 치료에 대한 투자 확대가 시장 성장에 더욱 기여하고 있습니다.
그러나 시장에는 첨단 치료법이나 인공 슬관절 치환술의 높은 비용, 개발도상국에서의 보험 환급 제한, 널리 승인된 질환 수정 치료법의 부족 등 몇 가지 제약이 존재합니다. 그럼에도 불구하고, 줄기세포 및 혈소판 농축 혈장(PRP) 요법 등 재생의료 기법의 활용 확대와 더불어, AI를 활용한 진단 및 디지털 헬스 솔루션의 도입이 퇴행성 슬관절염 시장에 새로운 성장 기회를 가져다줄 것입니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문에 걸친 잠재적 수익 기회를 규명하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한, 본 조사에서는 시장의 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 무릎 골관절염 시장의 주요 기업 개요를 작성하고 있습니다.
- 본 보고서의 인사이트를 활용함으로써, 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 ‘전 세계 무릎 골관절염 시장’ 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자분들은 전 세계 무릎 골관절염 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활한 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 무릎 골관절염 시장 : 약물 유형별, 2021-2033년
제5장 세계의 무릎 골관절염 시장 : 투여 경로별, 2021-2033년
제6장 세계의 무릎 골관절염 시장 : 유통 채널별, 2021-2033년
제7장 세계의 무릎 골관절염 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌 및 조사 방법
KSM 26.09.09Knee Osteoarthritis Market is estimated to be valued at USD 9,228.4 Mn in 2026 and is expected to reach USD 19,842.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9,228.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.60% | 2033 Value Projection: | USD 19,842.3 Mn |
Knee osteoarthritis (OA) is a progressive joint disease that slowly destroys the knee's cartilage causing pain, stiffness, swelling and limited movement. Knee osteoarthritis is one of the most common musculoskeletal diseases in the world and its prevalence is increasing due to ageing populations, obesity, sports injuries and sedentary lifestyles.
The knee osteoarthritis market is characterized by multiple segments such as medications for joint pain and inflammation, joint injections and visco supplements, orthotic aids, physiotherapies and a wide spectrum of surgical knee osteoarthritis treatment including knee replacement surgery. The market is witnessing growing interest in regenerative therapies, including platelet-rich plasma (PRP), stem cell therapies, and disease-modifying osteoarthritis drugs (DMOADs), supported by rising healthcare expenditure and continuous advancements in orthopedic care.
Market Dynamics
The global knee osteoarthritis market is driven by growing aging population, increasing prevalence of obesity, and growing incidence of joint injuries leading to a larger patient pool that needs long-term treatment. Growing awareness for early diagnosis, improving access to cutting-edge imaging technologies, and increasing investments in disease-modifying osteoarthritis drugs (DMOADs), biologics, and minimally invasive therapies are further contributing to the market growth.
However, a number of constraints are present in the market, such as high cost of advanced therapies and knee replacement procedures, limited reimbursement in developing countries, and lack of widely approved disease-modifying treatments. Nevertheless, expanding use of regenerative medicine modalities like stem cell and platelet-rich plasma (PRP) therapies, coupled with the implementation of AI-enabled diagnostics and digital health solutions will offer new opportunities for growth in knee osteoarthritis market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global knee osteoarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Sanofi, Bayer AG, GSK plc, Novartis AG, AbbVie Inc., Merck & Co., Inc., Johnson & Johnson, and Anika Therapeutics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global knee osteoarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global knee osteoarthritis market
Market Segmentation
- Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Hyaluronic acid
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Analgesics
- Corticosteroid
- Others
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Others
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Eli Lilly and Company
- Sanofi
- Bayer AG
- GSK plc
- Novartis AG
- AbbVie Inc.
- Merck & Co., Inc.
- Johnson & Johnson
- Anika Therapeutics, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Knee Osteoarthritis Market, By Drug Type
- Global Knee Osteoarthritis Market, By Route of Administration
- Global Knee Osteoarthritis Market, By Distribution Channel
- Global Knee Osteoarthritis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Knee Osteoarthritis Market, By Drug Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hyaluronic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Corticosteroid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Knee Osteoarthritis Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Knee Osteoarthritis Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Knee Osteoarthritis Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Company Profile
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Anika Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
